Feasibility of neonatal haemoglobin A1C as a biomarker for retinopathy of prematurity. (17th August 2020)

• Record Type: Journal Article
• Authors: Movsas, Tammy Z.; Muthusamy, Arivalagan
• Is Part Of: Biomarkers. Volume 25:Number 6(2020)
• Page Start: 468
• Page End: 473
• Publication Date: 2020-08-17
• Subjects: A1C -- retinopathy of prematurity -- ROP -- haemoglobin A1C -- dried blood spots -- glycated haemoglobin -- premature infants -- hyperglycaemia -- hypoglycaemia -- prematurity; Biochemical markers -- Periodicals; 610.28
• DOI: 10.1080/1354750X.2020.1783573
• Languages: English
• ISSNs: 1354-750X

Abstract

Abstract: Introduction: Retinopathy of prematurity (ROP) is a potentially serious eye disorder affecting very preterm infants. Non-proliferative ROP (NP-ROP), also known as Early Stage ROP, is characterized by deficient retinal angiogenesis. Proliferative ROP (P-ROP), also known as Late Stage ROP, is characterized by pathologic angiogenesis. The use of neonatal haemoglobin A1C as a biomarker for ROP has not yet been evaluated. Materials and methods: We modified the Haemoglobin A1C assay for use with neonatal dried blood spots (DBS) and then assessed A1C levels via Elisa immunoassay on DBS from 43 preterm infants (with gestational ages 26–28 weeks). We measured A1C on DBS collected at <1 week and 4 weeks of chronological age. Results: Compared to matched counterparts without ROP, there is significantly lower HbA1c in infants who develop NP-ROP, this occurs at Week 4 ( p= 0.004), but is not seen at Week 1; there is significantly higher HbA1c in infants with P-ROP, this occurs both at Week 1 ( p< 0.05) and Week 4 ( p= 0.005). Conclusions: The A1C test, modified for use with DBS, is a feasible biomarker for ROP; low A1C is a potential biomarker for non-proliferative ROP and high A1C is for proliferative ROP.